K2M gets consensus "Buy" rating — 5 key updates

Spinal Tech

K2M recently obtained a "Buy" rating from four brokerages covering the company, according to a Sleek Monkey report.

Here are five things to know:

 

1. Three brokers rated the company a "Buy" and one rated a "Sell," bringing the consensus to "Buy"

 

2. The company's average 12-month price among covering brokers is $29.33 in the last year.

 

3. Piper Jaffray analysts reiterated an "overweight" rating and set a price target of $29 in a note on Friday.

 

4. Zacks analysts downgraded K2M shares at the end of May from "hold" to "sell."

 

5. The company traded up today, hitting $24.74 and has a market cap of $981.06 million.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers